title: Johnson & Johnson Reports 45% Response Rate for Subcutaneous Amivantamab in Head and Neck Cancer Study
source: Yahoo
date: 2025-10-20
url: https://finnhub.io/api/news?id=d904d6a26a0169690491f35d5ea46582e8fadd70bcc7c4ca0fcc780c5fc9637d
Johnson & Johnson (JNJ) said Sunday that its subcutaneous formulation of amivantamab showed an overa
